E. Ferrer

发表

Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain)

Gemma Navarro, Elena Ferrer, Anna Esteve, 2008, Journal of acquired immune deficiency syndromes.

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti‐hepatitis B vaccination

E. Ferrer, B. Acevedo, G. Márquez, 2010, The journal of gene medicine.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Jessica G. Young, M. Hernán, J. Sterne, 2015, The lancet. HIV.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)

D. Podzamczer, B. Clotet, M. Plana, 2015, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

D. Podzamczer, B. Clotet, J. Gatell, 2009, Journal of acquired immune deficiency syndromes.

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

D. Podzamczer, B. Clotet, J. Miro, 2009, Journal of acquired immune deficiency syndromes.

Cervical cancer screening programs in Latin America and the Caribbean.

E. Lazcano-Ponce, E. Ferrer, R. Murillo, 2008, Vaccine.

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

D. Podzamczer, E. Negredo, E. Martinez, 2014, HIV medicine.

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.

L. Bruni, S. de Sanjosé, X. Castellsagué, 2010, The Journal of infectious diseases.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

Richard D Moore, J. Robins, M. Hernán, 2017, The lancet. HIV.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

D. Podzamczer, M. Plana, A. Cruceta, 2010, AIDS research and human retroviruses.

HIV-1 infected patients older than 50 years. PISCIS cohort study.

D. Podzamczer, B. Clotet, C. Tural, 2008, The Journal of infection.

Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or less

D. Podzamczer, E. Ribera, E. Ferrer, 2004, AIDS.

Immune Restoration in HIV-Positive, Antiretroviral-Naive Patients after 1 Year of Zidovudine/Lamivudine plus Nelfinavir or Nevirapine

D. Podzamczer, Felipe García, M. Plana, 2004, Antiviral therapy.

The continuum of HIV care in Catalonia

C. Tural, J. Miro, Gemma Navarro, 2015, AIDS care.

Elvitegravir concentrations in seminal plasma in HIV‐1‐infected men

D. Podzamczer, J. Niubó, L. Acerete, 2017, HIV medicine.

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.

Maria-Silvana Di Yacovo, D. Podzamczer, B. Clotet, 2015, The Journal of antimicrobial chemotherapy.

Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

D. Podzamczer, B. Clotet, S. Videla, 2011, AIDS research and human retroviruses.

Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine.

D. Podzamczer, E. Ferrer, F. Gudiol, 2000, AIDS.

Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression

D. Podzamczer, B. Clotet, J. Moltó, 2009, HIV clinical trials.

Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.

J. Mallolas, E. Ferrer, E. Pedrol, 2012, AIDS research and human retroviruses.

Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

C. Tural, M. Laguno, M. Crespo, 2010 .

Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls

D. Podzamczer, B. Clotet, E. Negredo, 2014, Journal of acquired immune deficiency syndromes.

Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons.

D. Podzamczer, F. Alcaide, E. Ferrer, 2011, Diagnostic microbiology and infectious disease.

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV‐1‐associated neurocognitive impairment during antiretroviral treatment switch

D. Podzamczer, J. Martinez-Picado, A. Prats, 2015, HIV medicine.

Comparative eff ectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

J. Sterne, C. Sabin, H. Furrer, 2015 .

Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.

D. Podzamczer, J. Gatell, J. Niubó, 2007, Journal of acquired immune deficiency syndromes.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

C. Morrison, F. Brun-Vézinet, F. Dabis, 2017, The Journal of antimicrobial chemotherapy.

SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

C. Solano, D. Navarro, R. Martino, 2021, American journal of hematology.

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

N. Muñoz, M. Schiffman, A. Burchell, 2008, Vaccine.

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

J. Romeu, Felipe García, A. Cruceta, 2000, AIDS.

A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)

D. Podzamczer, X. Badia, J. Miro, 2001, Antiviral therapy.

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

D. Podzamczer, E. Negredo, J. Gatell, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients

D. Podzamczer, E. Ferrer, A. Imaz, 2015, AIDS.

Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir.

D. Podzamczer, E. Ferrer, E. Van den Eynde, 2014, AIDS.

Response to Liposomal Doxorubicin and Clinical Outcome of HIV-1–Infected Patients with Kaposi’s Sarcoma Receiving Highly Active Antiretroviral Therapy

D. Podzamczer, J. González-lahoz, E. Ferrer, 2001, HIV clinical trials.

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

D. Podzamczer, J. Martinez-Picado, J. Niubó, 2016, The Journal of infectious diseases.

Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.

D. Podzamczer, M. Lejeune, Felipe García, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.

F. Catalá-López, S. de Sanjosé, F. Bosch, 2008, European journal of public health.

Thrice-Weekly Sulfadiazine-Pyrimethamine for Maintenance Therapy of Toxoplasmic Encephalitis in HIV-Infected Patients

D. Podzamczer, A. Cruceta, J. Miro, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability.

I. Catalá, D. Podzamczer, S. de Sanjosé, 2022, Sexually transmitted infections.

revalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1 ubtypes Among Patients with Recent Infection in Catalonia ( Spain ) between 003 and 2005

E. Ferrer, N. Margall, L. Matas, 2018 .

Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.

C. Tural, T. Pumarola, J. Miro, 2011, Enfermedades infecciosas y microbiologia clinica.

Recently acquired HIV infection in Spain (2003–2005): introduction of the serological testing algorithm for recent HIV seroconversion

C. Tural, T. Pumarola, J. Miro, 2008, Sexually Transmitted Infections.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz

D. Podzamczer, J. Gatell, A. León, 2005, Antiviral therapy.

Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08).

C. Tural, T. Pumarola, J. Miro, 2012, European journal of public health.

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

M. Tormo, M. Terol, C. Solano, 2023, Bone Marrow Transplantation.

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

C. Solano, D. Navarro, R. Martino, 2023, Blood Cancer Journal.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population

C. Tural, J. Miro, J. Caylà, 2018, BMJ Open.

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.

E. Ferrer, L. Álvarez-Lajonchere, Zaily Dorta Guridi, 2017 .

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

D. Podzamczer, S. Khoo, J. Niubó, 2018, Journal of NeuroVirology.

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.

B Clotet, B. Clotet, L. Ruiz, 2001, AIDS.

pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients.

D. Podzamczer, J. Niubó, J. Pérez, 1997, Scandinavian journal of infectious diseases.

Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

D. Podzamczer, J. Peña, S. Moreno, 2001, AIDS.

Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer

S. de Sanjosé, B. Lloveras, G. Sirera, 2012, PloS one.

Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk.

D. Podzamczer, E. Ferrer, C. Alonso-Villaverde, 2016, Atherosclerosis.

A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Elena Ferrer, D. Podzamczer, Daniel Podzamczer, 2003, The Journal of clinical endocrinology and metabolism.

[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].

D. Podzamczer, B. Clotet, C. Tural, 2005, Medicina clinica.

Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice.

D. Podzamczer, J. Pérez, E. Ferrer, 1999, Scandinavian journal of infectious diseases.

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.

D. Podzamczer, B. Clotet, C. Tural, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study

J. Robins, M. Hernán, S. Hernández-Díaz, 2016, Journal of acquired immune deficiency syndromes.

How much fat loss is needed for lipoatrophy to become clinically evident?

D. Podzamczer, E. Martinez, E. Ribera, 2009, AIDS research and human retroviruses.

Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine: 96-Week Results of a Randomized Study

D. Podzamczer, J. Gatell, J. Niubó, 2007, Journal of acquired immune deficiency syndromes.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals

Richard D Moore, J. Robins, M. Hernán, 2019, Statistics in medicine.

D. Podzamczer, X. Badia, J. Gatell, 2004, HIV clinical trials.

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.

D. Podzamczer, E. Negredo, E. Martinez, 2014, The Journal of antimicrobial chemotherapy.

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily

D. Podzamczer, J. Niubó, E. Ferrer, 2014, Journal of the International AIDS Society.

Etravirine concentrations in seminal plasma in HIV-infected patients.

D. Podzamczer, J. Niubó, E. Ferrer, 2013, The Journal of antimicrobial chemotherapy.

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.

Maria-Silvana Di Yacovo, D. Podzamczer, B. Clotet, 2014, The Journal of antimicrobial chemotherapy.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

M. Hernán, J. Sterne, C. Sabin, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

D. Podzamczer, J. Gatell, M. Arnedo, 2003, The Journal of infectious diseases.

Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.

D. Podzamczer, E. Negredo, J. Gatell, 2011, AIDS research and human retroviruses.

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

D. Podzamczer, J. Gatell, E. Ribera, 2005, AIDS (London).

Comparing dynamic monitoring strategies based on evolving CD4 cell counts in virologically suppressed HIV-positive individuals on cART: a prospective observational study in high-income countries

Richard D Moore, C. Sabin, S. Boswell, 2017, The lancet. HIV.

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease

R. Paredes, D. Podzamczer, B. Clotet, 2015, AIDS.

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.

D. Podzamczer, C. Tural, J. Miro, 2015, The Journal of antimicrobial chemotherapy.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

D. Podzamczer, S. Khoo, J. Niubó, 2018, Journal of NeuroVirology.

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.

D. Podzamczer, E. Negredo, E. Martinez, 2014, The Journal of antimicrobial chemotherapy.

Cervical cancer screening programs in Latin America and the Caribbean.

E. Lazcano-Ponce, E. Ferrer, R. Murillo, 2008, Vaccine.

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.

Maria-Silvana Di Yacovo, D. Podzamczer, B. Clotet, 2014, Journal of Antimicrobial Chemotherapy.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

B. Clotet, J. Romeu, A. Cruceta, 2000, Journal of acquired immune deficiency syndromes.